

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal**Topotecan for the second-line treatment of small cell lung cancer****Response to consultee and commentator comments on the matrix of consultees and commentators (pre-referral)**

Version of matrix of consultees and commentators reviewed:					
Matrix of consultees and commentators sent for consultation					
<i>Summary of comments, action taken, and justification of action:</i>					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>

National Institute for Health and Clinical Excellence

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of topotecan for the second-line treatment of small cell lung cancer

Issue date: August 2008

1.	<i>Merck Serono should be removed from the matrix as they no longer have a commercial interest in topotecan</i>	<i>Glaxo Smith Kline</i>		<i>Removed</i>	<i>This organisation no longer have a commercial interest in topotecan, and therefore are being removed from the manufacturer section of the matrix.</i>

National Institute for Health and Clinical Excellence

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of topotecan for the second-line treatment of small cell lung cancer

Issue date: August 2008